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Mordechai Mizrachi-Koren2,3,7, Stavit Shalev8, Dani Ben Amitai9, Annick Raas-Rothshild10,
Ayelet Adir-Shani11, Zvi-Uri Borochowitz7,12, Ruth Gershoni-Baruch7,13, Morad Khayat6, Daniela Landau14,
Gabriele Richard4,5, Reuven Bergman2,3,7, Jouni Uitto4, Moien Kanaan1 and Eli Sprecher2,3,7,15
Epidermolysis bullosa (EB) encompasses a large group of inherited blistering skin disorders caused by
mutations in at least 10 genes. Numerous studies, mainly performed in European and US families with EB, have
revealed a number of characteristic epidemiological and genetic features, which form the basis for current
diagnostic and counseling strategies. However, little is currently known about the molecular epidemiology of EB
in Middle East populations. In the present study, we assessed 55 EB families for pathogenic sequence alterations
in the 10 genes known to be associated with EB. Our results show unique EB subtype distribution and patterns
of inheritance in our cohort. We also failed to detect recurrent mutations frequently encountered in Europe and
the US, and did not consistently observe genotype–phenotype correlations formerly established in Western
populations. Thus, the molecular epidemiology of EB in the Middle East is significantly different from that
previously delineated in Europe and the US. Our data raise the possibility that similar differences may also be
found in other genetically heterogeneous groups of disorders, and indicate the need for population-specific
diagnostic and management approaches.
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INTRODUCTION
Epidermolysis bullosa (EB) is defined as a large, hetero-
geneous group of inherited mechanobullous disorders (Uitto
and Richard, 2005) resulting from mutations in genes coding
for various components of the cutaneous basement mem-
brane zone, a complex structure that anchors the epidermis
to the underlying dermis (Ghohestani et al., 2001).
EB is one of the most common inherited skin disorders
with a population prevalence of 19 in 1 million in the US, 32
in 1 million in Northern Ireland, and 49 in 1 million in
Scotland (McKenna et al., 1992; Horn et al., 1997; Fine et al.,
1999). Prevalence rates in Middle East populations are
unknown; however, the high frequency of consanguineous
unions characteristic of these populations (Zlotogora, 1997)
suggests that recessive types of EB may be more common in
this region. EB is associated with a high mortality rate and a
number of local and systemic complications, such as
infections, failure to thrive, anemia, esophageal and urethral
strictures, amyloidosis, and cancer (Uitto and Richard, 2005).
Therefore, EB generates a significant burden on medical
health systems, a problem of particular importance in
underprivileged areas of the world.
More than 30 different clinical EB variants have been
described (Fine et al., 2000), most of which can be assigned
to three major histopathological subtypes, as defined by
the microscopic location of the blisters: EB simplex (EBS;
MIM 131800, 131760, 131900), junctional EB (JEB; MIM
226700, 226650), and dystrophic EB (DEB; MIM 131750,
226600), characterized by blister formation within the
epidermal basal cell layer, the lamina lucida, and the
upper dermis, respectively. The majority of the families
with EBS show autosomal dominant inheritance pattern;
all forms of JEB are transmitted in an autosomal recessive
fashion, while inheritance in DEB can be either autosomal
recessive or autosomal dominant (Uitto and Richard,
2005).
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To date, mutations in 10 distinct genes have been found to
cause EB (Uitto and Richard, 2005). Each of the proteins
encoded by these 10 genes plays a critical role in the function
of the basement membrane, and abnormal function of any of
these results in a defined EB subtype with a fairly predictable
associated phenotype (Marinkovich, 1999; Uitto and Pulkki-
nen, 2001). Mutations in the genes encoding keratins 5 and
14 (KRT5 and KRT14) have been shown to underlie EBS;
mutations in the genes encoding the three subunit polypep-
tides of laminin 5 (LAMA3, LAMB3, and LAMC2) have been
shown to cause JEB; and mutations in the gene coding for
type VII collagen (COL7A1) have been shown to result in
DEB (Uitto and Richard, 2005). Five additional genes have
been reported to harbor mutations in less frequent variants of
EB: mutations in PLEC1, coding for plectin, cause EB with
late-onset muscular dystrophy (MIM 226670), the Ogna
variant of EBS (MIM 131950), EB with pyloric atresia (MIM
226730), and a recently described lethal form of JEB
(Charlesworth et al., 2003; Pfendner et al., 2005); mutations
in ITGA6 and ITGB4, which code for the two subunits
of integrin a6b4, may be responsible for EB with pyloric
atresia, but also for EBS or JEB without gastrointestinal
manifestations (Inoue et al., 2000; Jonkman et al., 2002);
mutations in COL17A1, coding for type XVII collagen, were
found to cause generalized atrophic benign EB, a nonlethal
variant of JEB (Bauer and Lanschuetzer, 2003; Uitto and
Richard, 2005), as well as a mild form of EBS (Huber et al.,
2002).
In the past, the majority of genetic studies of EB have
focused on European and US populations, and little is
currently known about the clinical and molecular features
of this group of diseases in other parts of the world, including
the Middle East. Several preliminary reports (Nakano et al.,
2002b; Ciubotaru et al., 2003; Indelman et al., 2005) have
suggested that the demographic features specific to the
Middle East may underlie a number of unique epidemiolo-
gical and biological attributes characteristic of EB patients in
this region. In the present study, we report the cumulative
data obtained for 55 EB families originating from Israel and
Palestine.
RESULTS AND DISCUSSION
Distribution of EB subtypes and clinical features
A total of 55 families diagnosed with EB on the basis of
typical clinical and histopathological features underwent a
formal genetic analysis (Tables S1–S3). EBS, JEB, and DEB
represented 40, 27, and 33% of the cohort, respectively
(Figure 1a). As compared with data previously collected in
various countries (ie Japan, Norway, Northern Ireland, and
United States) (McKenna et al., 1992; Fine et al., 1999)
(Figure 1b), the percentage of dominant EBS cases in the
present series was significantly low. This may have resulted
from the high proportion of recessive EB subtypes in our
cohort, which in turn may be due to the high inbreeding
coefficient characteristic of populations of the Middle East
(Zlotogora, 1997). This assumption is supported by the
observation that only 48% of the Israeli EB patients were of
Jewish background, despite the fact that the Jewish popula-
tion, characterized by a low rate of consanguineous
marriages, accounts for more than 80% of the Israeli popu-
lation (http://www.mfa.gov.il/MFA/MFAArchive/2000_2009/
2004/).
According to a study in Northern Ireland (McKenna et al.,
1992) and the report of the National EB Registry (Fine et al.,
1999), JEB represents approximately 2–5% of all EB cases in
Western populations. However, this EB subtype accounted
for 27% of the cases in our series, once again pointing to the
higher prevalence of recessive disorders in Middle East
populations (Alwan and Modell, 2003), albeit JEB appears to
be relatively rare in the Israeli Jewish population (Table S2).
Of note, in a previous survey of 49,902 patients in a general
clinic in Saudia, no JEB cases were reported (Abahussein
et al., 1993). However, it is not clear how the diagnosis of the
various EB subtypes was approached and if it was skewed
towards non-lethal EB subtypes, since the study was
conducted in an outpatient setting, thus underestimating the
prevalence of severe/lethal JEB cases.
For the DEB subtype, the proportion of DEB cases relative
to the total number of families was comparable to that
reported in the US population (Fine et al., 1999) (Table S3).
However, a significantly higher percentage of the cases
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Figure 1. Distribution of the various EB subtypes. The data collected in the
present study are shown in (a). The data reported by the National EB Registry
(Fine et al., 1999) are shown for comparison in (b). EB-WC, EBS
Weber–Cockayne type characterized by involvement of hands and soles; EB-
K, EBS Koebner type, characterized by generalized involvement; EB-DM, EBS
Dowling–Meara type, characterized by generalized herpetiform skin blistering
accompanied by mucosal involvement; JEB-H, JEB Herlitz type characterized
by perinatal lethality; JEB-NH, JEB non-Herlitz type, characterized by survival
through early childhood; JEB-PA, JEB associated with pyloric atresia; HS-
RDEB, recessive DEB Hallopeau–Siemens type characterized by extensive
skin and mucosal blistering and scarring; RDEB, recessive DEB; DDEB,
dominant DEB; UC, unclassified.
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displayed a recessive mode of inheritance as compared with
that recorded by the National EB Registry (Fine et al., 1999).
Molecular features
Mutation analysis was concordant with the histopathological
diagnosis in all cases. A total of 50 different mutations were
identified in the 55 families of our cohort, 17 of which have
not been previously reported.
EB simplex (Table S1). Altogether, 22 EBS cases were
assessed. In all, 14 cases (64%) were due to mutations in
KRT14, while only a minority of the cases was caused by
sequence alterations in KRT5 (36%).
Autosomal recessive EBS, the least prevalent type of EBS in
Western countries with only a few sporadic cases reported
(reviewed in Indelman et al., 2005), represented in our cohort
approximately one-third of EBS cases. Mutations W305X and
R134C were carried by patients of Arab Moslem origin, while
Q396X most probably originated from Transylvania and was
found in families of Jewish Ashkenazi origin only (Ciubotaru
et al., 2003; Indelman et al., 2005).
We identified two patients with EBS harboring a hetero-
zygous mutation, R388H, which was previously reported in a
recessive case of EBS (Ciubotaru et al., 2003). No other
mutations in KRT5 or KRT14 were detected in these two
affected individuals and R388H was not found in more than
200 population-matched control individuals (400 chromo-
somes). Moreover, the R388 residue is highly conserved
among keratin molecules (ConSeq score¼9; range 1–9;
http://conseq.bioinfo.tau.ac.il). Despite this strong evidence
for R388H being a disease-causing mutation, R388H was
also detected in the healthy father of two affected children
carrying R388H and a maternal nonsense mutation in KRT14
(Ciubotaru et al., 2003), suggesting lack of penetrance for
R388H or underlying paternal mosaicism in this specific
kindred.
In Western populations, mutations affecting codon 125 of
KRT14 have been shown to cause more than 40% of all EBS
cases (Sybert and Stephens, 1994; Fine et al., 1999);
however, only two such cases (9%) were identified in our
series. This result emphasizes again the profound differences
in the molecular epidemiology of EB between Middle Eastern
and Western populations.
Junctional EB (Table S2). In all, 15 families with JEB were
assessed, and a total of 15 mutations were identified.
Previous data, mainly collected in US and European
populations, had revealed the following facts: most mutations
causing JEB are found in the LAMB3 gene; two hot spot
mutations, R635X and R42X, account for 50% of the
mutations carried by JEB patients; nonsense/frameshift muta-
tions, in contrast to missense mutations, are almost always
associated with a poor prognosis; and mutations in COL17A1
are associated with a benign disease course (Nakano et al.,
2000, 2002b; Bauer and Lanschuetzer, 2003).
Mutation analysis performed in our cohort failed to
confirm these previous findings. For example, mutations
were almost evenly distributed between the four JEB genes:
LAMA3 (27%), LAMB3 (33%), LAMC2 (13%), and COL17A1
(20%), with a single case associated with PA being caused by
mutations in ITGB4. In addition, the hot spot mutations
R635X and R42X, causing JEB without pyloric atresia, were
found in 0 of 30 and 1 of 30 mutant alleles, respectively.
Finally, there was no definitive correlation between the
nature of the mutation-carrying gene or the type of the
causative mutation and the course of the disease, thus
confirming our previous preliminary data (Nakano et al.,
2002b): nonsense and frameshift mutations resulted in a
lethal phenotype and missense mutations caused a nonlethal
phenotype in eight out of 11 cases due to mutations in
laminin 5-encoding genes (Table S2). In addition, we report
here the first case of lethal JEB caused by a homozygous
mutation in COL17A1, 4144del4. Since the affected child
carrying this mutation received intensive treatment in a
modern tertiary hospital, the severe course of his disease
cannot be attributed to poor medical care. Of note, the
parents of this patient reported that a second child in this
family, who was not examined, also died shortly after birth
due to extensive skin blistering.
Dystrophic EB (Table S3). Of the 18 DEB cases caused by
deleterious mutations in COL7A1 (Table S3), 11 (61%) dis-
played a recessive mode of inheritance, while the remaining
were inherited in an autosomal dominant manner. In one
recessive case, despite sequencing of the entire coding region
of the gene, only one mutation could be identified, suggesting
the existence of an additional causative mutation in noncod-
ing regions of the gene. Half of the mutations identified in our
patients were novel, suggesting that COL7A1 mutations are
often unique to individual families or ethnic groups (Salas-
Alanis et al., 2000; Murata et al., 2004). However, the hot
spot mutation G2043R (Christiano et al., 1995) was identified
in two Jewish families. In contrast to our results for EBS and
JEB in this cohort, genotype–phenotype correlation analysis of
the DEB cases did not reveal unusual findings. Recessive
inheritance was often predictive of poor prognosis, as
reported previously (Gardella et al., 2002).
Implication for EB patient care in the Middle East
The results of this study carry important implications for the
care of EB patients in the Middle East.
First, genetic counseling of families at risk for EB should
rely upon a combined clinical, histological, and molecular
analysis. For example, the inheritance pattern of EBS cannot
be determined based on clinico-pathological grounds alone
(Table S1), and requires molecular confirmation due to the
relatively high prevalence of autosomal recessive keratin
mutations. Conversely, the presence of specific genetic
mutations in an EB family does not always allow predicting
the course and outcome of the disease, calling for caution in
interpreting these data for the purpose of genetic counseling.
Indeed, in this and a previous study (Nakano et al., 2002b),
we identified JEB cases due to nonsense mutations, which did
not result in a lethal phenotype as generally assumed. On the
other hand, we report here a case of lethal JEB caused by a
mutation in COL17A1, despite the fact that all previously
www.jidonline.org 779
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reported mutations in this gene were associated with a rather
benign course (Bauer and Lanschuetzer, 2003).
Second, diagnostic strategies based upon molecular
epidemiological features determined in populations of
Western origin may not be applicable to Middle Eastern
populations, possibly due to marked demographic differ-
ences, in particular consanguineous marriages. The low
prevalence of known hot spot mutations (eg R125H/C in
KRT14, R635X in LAMB3) as well as the lack of preponder-
ance of mutations in given genes (eg LAMB3 in JEB) (Tables
S1 and S2) indicate the need for specific diagnostic
algorithms adapted to the molecular features of EB in Middle
Eastern populations. Indeed, our data suggest that mutation
analysis should be prioritized according to ethnic (eg Q196X
in KRT14 in patients of Jewish Austro-Hungarian origin) or
geographic (eg Q1083X in LAMB3 in patients of Arab
Moslem origin living in Northern Israel) origins of EB patients.
Third, the fact that genotype–phenotype correlations firmly
established in Western populations are not consistently
observed in a Middle Eastern population suggests the
existence of inherited, epigenetic, or environmental modifier
traits, which are responsible for modulating the clinical
expression of pathogenic mutations in EB, as has previously
been shown in some individual cases in the past (McGrath
et al., 1999; Bodemer et al., 2003). The identification of these
factors in Middle East populations may be instrumental in
developing a comprehensive strategy for the counseling of
families at risk for EB in this geographic region.
MATERIALS AND METHODS
Patients and biological materials
Families were recruited in Israel over a period of 5 years by actively
searching all available registries at our institutions as well as by
publicizing our efforts during professional meetings. All participants
or their legal guardian provided written and informed consent
according to a protocol previously approved by the local Helsinki
Committee and by the National Committee for Genetic Human
Research of the Israeli Ministry of Health in accordance with the
Declaration of Helsinki Principles. Blood samples were drawn from
all family members and DNA was extracted according to standard
procedures. EB diagnosis and subtyping were determined based on
light microscopy and electron microscopy examination of skin
biopsies as described previously (Bergman, 1999; Petronius et al.,
2003).
Mutation analysis
Genomic DNA was PCR-amplified using primer pairs encompassing
all exons and exon–intron boundaries of the 10 genes known to be
associated with EB as described previously (McGrath et al., 1995a;
Kon et al., 1997; Takizawa et al., 1997; Rouan et al., 2000; Nakano
et al., 2002a; Ciubotaru et al., 2003). For the KRT5 and KRT14
genes, amplicons were immediately gel-purified (QIAquick gel
extraction kit, Qiagen, Valencia, CA) and subjected to bidirectional
DNA sequencing using the BigDye terminator system on an ABI
Prism 3100 sequencer (PE Applied Biosystems, Foster City, CA).
DNA sequence analysis was performed using the Sequencher
platform. For mutational screening in other genes (LAMA3, LAMB3,
LAMC2, COL17A1, ITGB4, ITGA6, PLEC, and COL7A1), we used
conformation-sensitive gel electrophoresis or dHPLC (Transge-
nomics, Omaha, NE) to screen PCR products for heteroduplex
formation prior to direct sequencing (Pfendner et al., 2003). All
novel mutations were excluded from at least 100 control individuals
using either direct sequencing or PCR-restriction fragment length
polymorphism.
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